Joseph Walter Vazzano
Known title: Chief Financial OfficerCIK: 0001715291
Joseph Walter Vazzano's purchase track record
How the stock did after each of Joseph Walter Vazzano's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since November 18, 2022
Stock higher 6 months later
67%
3 months: 67%
Median 6-month return
+98.8%
3 months: +24.5%
Beat the S&P 500
67%
median +83.2% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/25/2024 | ABEO | $18K | +57.7% | +98.8% | +15.1% |
| 9/19/2023 | ABEO | $11K | +24.5% | +99.7% | +16.5% |
| 11/18/2022 | ABEO | $10K | -41.1% | -23.3% | +5.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ABEO | ▼ Sell | Open Market | 9,191 | $47K | 9/29/2026 | View on chart |
| ABEO | ▼ Sell | Open Market | 1,478 | $10K | 7/21/2026 | View on chart |
| ABEO | ▼ Sell | Open Market | 24,880 | $173K | 7/9/2026 | View on chart |
| ABEO | ▼ Sell | Open Market | 13,421 | $71K | 6/9/2026 | View on chart |
| ABEO | ▼ Sell | Open Market | 25,646 | $138K | 6/9/2026 | View on chart |
| ABEO | ▼ Sell | Open Market | 10,271 | $56K | 6/8/2026 | View on chart |
| ABEO | ▼ Sell | Open Market | 785 | $4K | 3/16/2026 | View on chart |
| ABEO | ▼ Sell | Open Market | 18,666 | $100K | 1/22/2026 | View on chart |
| ABEO | ▲ Buy | Grant | 133,595 | $0 | 1/20/2026 | View on chart |
| ABEO | ▼ Sell | Open Market | 9,035 | $49K | 9/29/2025 | View on chart |
| ABEO | ▼ Sell | Open Market | 15,000 | $110K | 8/15/2025 | View on chart |
| ABEO | ▼ Sell | Open Market | 1,502 | $10K | 7/22/2025 | View on chart |
| ABEO | ▼ Sell | Open Market | 25,411 | $149K | 7/9/2025 | View on chart |
| ABEO | ▼ Sell | Open Market | 17,795 | $120K | 6/6/2025 | View on chart |
| ABEO | ▲ Buy | Grant | 13,333 | $0 | 6/5/2025 | View on chart |
| ABEO | ▼ Sell | Tax Withholding | 685 | $4K | 3/14/2025 | View on chart |
| ABEO | ▲ Buy | Grant | 144,509 | $0 | 1/21/2025 | View on chart |
| ABEO | ▼ Sell | Tax Withholding | 6,388 | $38K | 9/28/2024 | View on chart |
| ABEO | ▼ Sell | Tax Withholding | 1,055 | $5K | 7/21/2024 | View on chart |
| ABEO | ▲ Buy | Grant | 155,200 | $0 | 7/8/2024 | View on chart |
| ABEO | ▼ Sell | Tax Withholding | 16,408 | $74K | 6/5/2024 | View on chart |
| ABEO | ▲ Buy | Open Market | 5,608 | $18K | 4/25/2024 | View on chart |
| ABEO | ▼ Sell | Tax Withholding | 703 | $6K | 3/15/2024 | View on chart |
| ABEO | ▼ Sell | Tax Withholding | 6,230 | $24K | 9/29/2023 | View on chart |
| ABEO | ▲ Buy | Open Market | 14 | $52 | 9/19/2023 | View on chart |
| ABEO | ▲ Buy | Open Market | 2,986 | $11K | 9/19/2023 | View on chart |
| ABEO | ▼ Sell | Tax Withholding | 1,187 | $4K | 7/24/2023 | View on chart |
| ABEO | ▲ Buy | Grant | 141,908 | $0 | 6/5/2023 | View on chart |
| ABEO | ▼ Sell | Tax Withholding | 792 | $2K | 3/15/2023 | View on chart |
| ABEO | ▲ Buy | Open Market | 2,500 | $10K | 11/18/2022 | View on chart |
| ABEO | ▲ Buy | Grant | 72,750 | $0 | 9/28/2022 | View on chart |
| ABEO | ▲ Buy | Grant | 12,000 | $0 | 7/21/2022 | View on chart |
| ABEO | ▲ Buy | Grant | 200,000 | $0 | 3/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Abeona Reports ZEVASKYN Launch Momentum and Revenue Growth
Abeona Therapeutics highlighted positive momentum for its ZEVASKYN product launch and revenue growth during a recent H.C. Wainwright event. The company is also expanding its distribution network as the treatment for RDEB gains traction. These developments provide fundamental context for the stock, which is currently trading near its 52-week low.
Abeona Reports ZEVASKYN Launch Momentum and Revenue Growth. Abeona Therapeutics highlighted positive momentum for its ZEVASKYN product launch and revenue growth during a recent H.C. Wainwright event. The company is also expanding its distribution network as the treatment for RDEB gains traction. These developments provide fundamental context for the stock, which is currently trading near its 52-week low.